Animal studies are considered but must demonstrate novel signalling pathways underlying disease or describe novel therapeutic interventions, and have significant clinical relevance.
Papers that are predominantly methodological or that present hypotheses or models unsupported by original data are not suitable.
The current approximate turnaround times are: Rejection without peer review: 2 days Submission to first decision: 4 weeks Acceptance to receipt of proofs: 4 weeks Acceptance to online publication: 8.5 weeks All papers submitted to are seen by one or more members of the Editorial Board.
At this stage, some are rejected without peer review owing to lack of novelty, involvement of normal subjects, serious scientific flaws or work lying outside the scope of the journal.
More detailed studies of single cases may - in rare instances - be considered as a Report (see below) only when they resolve definitively an important problem in the field or when the data lead to a significant conceptual advance.
Studies of single cases that can be readily performed on groups of patients will not be considered.8 Reviews provide a comprehensive and scholarly account of a topic that has direct relevance to clinical neuroscience and that has not recently been covered in the literature.
Normally these are authored by individuals who have themselves made a significant contribution to the original literature on the topic under review and are acknowledged authorities in the field.
Meta-analyses and systematic reviews of the literature are not considered either as original articles or reviews.
All accepted manuscripts undergo a process of in-house copy-editing for style, prior to production.
The proofs are then emailed to the author for final checking.